Scholar Rock Holding Co. (NASDAQ:SRRK - Get Free Report)'s share price shot up 5.8% on Monday . The company traded as high as $43.50 and last traded at $42.85. 533,328 shares traded hands during mid-day trading, a decline of 40% from the average session volume of 887,089 shares. The stock had previously closed at $40.49.
A number of analysts have commented on SRRK shares. JPMorgan Chase & Co. boosted their price objective on Scholar Rock from $18.00 to $31.00 and gave the stock an "overweight" rating in a report on Monday, October 14th. HC Wainwright upped their price objective on Scholar Rock from $40.00 to $50.00 and gave the company a "buy" rating in a research note on Tuesday, November 26th. Piper Sandler boosted their target price on shares of Scholar Rock from $28.00 to $42.00 and gave the company an "overweight" rating in a research note on Tuesday, October 15th. Truist Financial raised their target price on Scholar Rock from $36.00 to $45.00 and gave the stock a "buy" rating in a research report on Monday, November 25th. Finally, Wedbush reaffirmed an "outperform" rating and issued a $47.00 price objective on shares of Scholar Rock in a report on Thursday. Six investment analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat.com, Scholar Rock currently has a consensus rating of "Buy" and a consensus price target of $40.43.
View Our Latest Report on SRRK
The company has a market cap of $3.99 billion, a PE ratio of -18.13 and a beta of 0.52. The company has a quick ratio of 3.88, a current ratio of 3.88 and a debt-to-equity ratio of 0.63. The stock has a 50-day moving average of $37.85 and a 200-day moving average of $21.84.
In other Scholar Rock news, major shareholder Public Equities L.P. Invus sold 409,433 shares of the stock in a transaction that occurred on Monday, November 25th. The shares were sold at an average price of $38.49, for a total transaction of $15,759,076.17. Following the transaction, the insider now directly owns 10,850,005 shares in the company, valued at $417,616,692.45. This trade represents a 3.64 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. 19.20% of the stock is owned by insiders.
A number of institutional investors have recently made changes to their positions in the business. Clearbridge Investments LLC purchased a new stake in Scholar Rock during the second quarter valued at about $6,223,000. Fisher Asset Management LLC boosted its holdings in Scholar Rock by 593.6% during the 3rd quarter. Fisher Asset Management LLC now owns 734,019 shares of the company's stock valued at $5,879,000 after acquiring an additional 628,186 shares during the period. Millennium Management LLC grew its position in Scholar Rock by 159.2% during the 2nd quarter. Millennium Management LLC now owns 925,584 shares of the company's stock worth $7,710,000 after acquiring an additional 568,512 shares during the last quarter. Marshall Wace LLP increased its stake in Scholar Rock by 1,051.3% in the 2nd quarter. Marshall Wace LLP now owns 487,285 shares of the company's stock worth $4,059,000 after purchasing an additional 444,961 shares during the period. Finally, FMR LLC increased its stake in Scholar Rock by 3.1% in the 3rd quarter. FMR LLC now owns 10,196,046 shares of the company's stock worth $81,670,000 after purchasing an additional 308,813 shares during the period. Hedge funds and other institutional investors own 91.08% of the company's stock.
Scholar Rock Holding Corporation, a biopharmaceutical company, focuses on the discovery, development, and delivery of medicines for the treatment of serious diseases in which signaling by protein growth factors plays a fundamental role. The company develops Apitegromab, an inhibitor of the activation of myostatin that is in Phase 3 clinical trial for the treatment of spinal muscular atrophy; and SRK-181, which has completed Phase 1 clinical trials for the treatment of cancers that are resistant to checkpoint inhibitor therapies, such as anti-PD-1 or anti-PD-L1 antibody therapies.
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Scholar Rock, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Scholar Rock wasn't on the list.
While Scholar Rock currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.